Celldex Therapeutics, Inc. (CLDX) stock analysis
CLDX · Celldex Therapeutics, Inc.
Latest recorded price: USD 28.59
Sector and industry: Healthcare · Biotechnology
Fiscal 2025 figures: revenue growth -13.1%, free cash flow margin -13,829.1%. The model flags 2 risk signals for this company (2 high severity).
Similar companies in Healthcare
- Corcept Therapeutics Incorporated - Common Stock (CORT)
- CRISPR Therapeutics AG - Common Shares (CRSP)
- Cytokinetics, Incorporated (CYTK)
- Denali Therapeutics Inc. - Common Stock (DNLI)
- Dianthus Therapeutics, Inc. (DNTH)
- Exelixis, Inc. - Common Stock (EXEL)
- Fortrea Holdings Inc. - Common Stock (FTRE)
- Halozyme Therapeutics, Inc. (HALO)